• A Bioequivalence Comparison Between the Once-Daily Extended-Release Tablet and the Twice-Daily Tablet Formulations of Deutetrabenazine at Steady State
• A Case of Oral-Buccal-Lingual Dyskinesia and Neuropsychiatric Symptoms After Prolonged Levetiracetam Exposure
• A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database
• A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia
• A Rare Case of Phentermine-Related Tardive Dyskinesia
• Accelerated anodal transcranial direct current stimulation targeting cerebellum and primary motor cortex in the management of tardive dyskinesia: A case study
• An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders
• An experience of using Clozapine in elderly patients with mental disorders
• Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association
• Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia
• Anterior capsulotomy combined with subthalamic nucleus deep brain stimulation for tardive dystonia
• Associations between Catechol-O-methyltransferase (COMT) polymorphisms and cognitive impairments, psychiatric symptoms and tardive dyskinesia in schizophrenia
• Associations between polymorphisms in the cannabinoid receptor 1 gene, cognitive impairments and tardive dyskinesia in a Chinese population with schizophrenia
• Atypical extrapyramidal manifestation of a typical antipsychotic with serotonergic antidepressant
• Auditory and Visual Hallucinations in a Congenitally Deaf Patient with Schizophrenia: A Case Report and Brief Literature Review
• Bacillus Calmette-Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats
• Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research
• Clebopride-Associated Movement Disorders
• Clinical quandaries in psychotic disorders: the road is long, with many a winding turn
• Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington's Disease and Tardive Dyskinesia
• Clozapine Prescripers-Dogmatic or Pragmatic?
• Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review
• Correction: Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
• Crushing the Contents of Valbenazine Capsules for Potential Addition to Soft Foods or Administration via Gastrostomy Tube
• Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment
• Daytime bruxism, tardive orofacial dyskinesia, and dysphagia as side effects to duloxetine use over nine years in an octogenarian
• Delayed Presentation of Antipsychotic Withdrawal Tardive Dyskinesia: A Case Report
• Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study
• Early Onset of Tardive Dyskinesia in an Antipsychotic-Naive Patient Treated With Low-Dose Cariprazine
• Effect of rs1108580 of DBH and rs1006737 of CACNA1C on Cognition and Tardive Dyskinesia in a North Indian Schizophrenia Cohort
• Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis
• Efficacy and safety of Transcranial Direct Current Stimulation (tDCS) on cognitive function in chronic schizophrenia with Tardive Dyskinesia (TD): a randomized, double-blind, sham-controlled, clinical trial
• Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study
• Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review
• First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database
• Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database
• Genetic Susceptibility to Tardive Dyskinesia and Cognitive Impairments in Chinese Han Schizophrenia: Role of Oxidative Stress-Related and Adenosine Receptor Genes
• Genome-wide DNA methylation analysis in schizophrenia with tardive dyskinesia: a preliminary study
• Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant
• Haloperidol-induced painless legs and moving toe syndrome in a schizophrenia patient: a case report
• Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications
• Illustration of the Dramatic and Dynamic Efficacy of Chronic GPi-DBS Therapy in a Patient with Tardive Dyskinesia/Dystonia
• Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia
• Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
• Implementation of Pharmacist-Led Medication Review Service for Parkinson's Disease Patients Admitted for Deep Brain Stimulation
• Improvement of Tardive Dyskinesias with Olanzapine
• Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative
• Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results
• Involvement of Antioxidant and Prevention of Mitochondrial Dysfunction, Anti-Neuroinflammatory Effect and Anti-Apoptotic Effect: Betaine Ameliorates Haloperidol-Induced Orofacial Dyskinesia in Rats
• Levodopa/Carbidopa to Augment the Treatment of Amblyopia: A Report by the American Academy of Ophthalmology
• Management of Cholinergic Rebound After Abrupt Withdrawal of Clozapine: A Case Report and Systematic Literature Review
• Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis
• Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database
• Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system
• Multiple therapies relieve long-term tardive dyskinesia in a patient with chronic schizophrenia: A case report
• Neglect of Adverse Effects in Treatment Guidelines for Depression
• Neurological perspectives should be integrated into the management of tardive dyskinesia - expert opinion and proposed educational initiatives in Asia
• Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review
• Oleanolic acid alleviates the extrapyramidal symptoms and cognitive impairment induced by haloperidol through the striatal PKA signaling pathway in mice
• Overview of Movement Disorders Secondary to Drugs
• Pimozide-induced tardive dyskinesia in the treatment of delusions of infestation
• Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia
• Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease
• Putative role of immune reactions in the mechanism of tardive dyskinesia
• Real-world experience with VMAT2 inhibitors in Tourette syndrome
• Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications
• Regional Homogeneity in schizophrenia patients with tardive dyskinesia: a resting-state fMRI study
• Relapse of Tardive Dyskinesia Following Successful Treatment With Amantadine: A Case Report
• Reversible Dysphagia Associated With Risperidone Presenting With a Choking Episode
• Review of Dopamine Antagonists for Nausea and Vomiting in Palliative Care Patients
• Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report
• Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database
• Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
• Severe Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Following the Initiation of Valbenazine for Tardive Dyskinesia: A Case Report
• Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia
• Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia
• Tardive dyskinesia
• Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway
• Tardive Dyskinesia Suppressed With Ginkgo Biloba
• Tardive Dyskinesia Suppressed With Ginkgo Biloba
• Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review
• Tardive Dyskinesia With Chorea-Ballism Improved by Valbenazine: A Case Report
• Tardive dyskinesia's under-recognition in the era of COVID-19
• The Challenge of Managing Refractory Psychosis Amid Multiple Medication Side Effects: A Case Report and Review of the Literature
• The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia
• The effect of Oenothera biennis (Evening primrose) oil on inflammatory diseases: a systematic review of clinical trials
• The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties
• The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics
• The introduction of clozapine at the Nathan Kline Institute in New York and its long-term consequences
• The Outcome of Antipsychotics-induced Tardive Syndromes: A Ten-year Follow-up Study
• The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity: A Scoping Review
• The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation
• The value of re-evaluation and thorough family history taking for the diagnostic work-up of chorea
• Transcranial direct current stimulation improves tardive dyskinesia in long-term hospitalized patients with chronic schizophrenia
• Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines
• Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report
• Treatment of tardive dyskinesia with clonazepam: A case report
• Unveiling the Unprecedented: An Astonishing Rarity of Metoclopramide Hydrochloride-Triggered Nystagmus in a Pregnant Woman
• Valbenazine for tardive dyskinesia: a systematic review and network meta-analysis
• Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development